DEF 14A: Minerva Neurosciences Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals

Minerva Neurosciences will hold its annual stockholders meeting virtually on December 5, 2024, to vote on director elections, executive compensation, and auditor ratification.

Summary

• Minerva Neurosciences, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on December 5, 2024, at 9:30 a.m. Eastern Time.
• Stockholders of record as of October 7, 2024, are eligible to vote.
• The meeting will address the election of two Class I directors (Hans Peter Hasler and Dr. Remy Luthringer), an advisory vote on executive compensation, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board recommends voting FOR the election of the director nominees, FOR the advisory vote on executive compensation, and FOR the ratification of the selection of Deloitte & Touche LLP.
• Stockholders can vote online, by phone, or by mail before the meeting, or virtually during the meeting.
• The company is providing access to proxy materials over the internet.
• A list of stockholders will be available for examination ten days prior to the meeting and during the meeting.
• The Board has determined that Hans Peter Hasler, Dr. David Kupfer, Dr. Fouzia Laghrissi-Thode, and Jan van Heek are independent directors.
• Dr. Remy Luthringer serves as both Chief Executive Officer and Board Chair, with Dr. Kupfer as the lead independent director.
• The Board oversees risk management through the full Board and its committees.
• Officers and directors are prohibited from hedging, pledging, and speculative transactions involving the company's securities.
• The company has a Code of Business Conduct and Ethics applicable to all officers, directors, and employees.
• The Nominating and Corporate Governance Committee will consider stockholder recommendations for director candidates.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting information in a neutral and factual manner. The sentiment is moderately positive as it outlines routine corporate governance procedures and seeks stockholder input.

Positives

• The company is facilitating increased stockholder participation through a virtual meeting format.
• The Board has a lead independent director to balance the combined Chief Executive Officer/Board Chair role.
• The company has a Code of Business Conduct and Ethics applicable to all officers, directors, and employees.
• The Nominating and Corporate Governance Committee will consider stockholder recommendations for director candidates.

Risks

• If a nominee becomes unavailable for election, shares will be voted for a substitute nominee proposed by the Board.
• Broker non-votes on Proposals 1 and 2 will have no effect and will not be counted towards the vote total for any of those proposals.
• The say-on-pay vote is advisory and not binding on the company.

Future Outlook

The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment.

Management Comments

• We believe hosting a virtual meeting enables increased stockholder participation and improves meeting efficiency and our ability to communicate effectively with our stockholders, while lowering the cost of conducting the Annual Meeting.
• The Company believes that combining the positions of Chief Executive Officer and Board Chair helps to ensure that the Board and management act with a common purpose and provides a single, clear chain of command to execute the Company's strategic initiatives and business plans.

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including proxy statements, annual meetings, and board committee structures. The virtual meeting format aligns with a growing trend to increase accessibility and reduce costs.

Comparison to Industry Standards

• The board independence criteria align with Nasdaq listing standards, similar to other publicly listed companies.
• The compensation committee's engagement of Radford as a compensation consultant is a common practice to ensure executive compensation is competitive and aligned with market practices.
• The related person transaction policy is consistent with SEC regulations and aims to prevent conflicts of interest, a standard practice among public companies.
• The company's clawback policy aligns with the Dodd-Frank Wall Street Reform and Consumer Protection Act and applicable Nasdaq rules, similar to other publicly listed companies.

Management Changes

Corporate Governance

Related Party Transactions

• In 2022 and 2023, the Company paid PPRS Research, Inc. approximately $2.9 million and $2.1 million, respectively, for program and project management services, including research and development services and coordination with investigators and contract research organizations.
• In 2022 and 2023, the Company paid Dr. Saoud approximately $603,000 and $541,000, respectively, for consulting services.

Stakeholder Impact

• Stockholders have the opportunity to vote on key company matters.
• Executive officers and directors are subject to policies regarding hedging, pledging, and speculative transactions.
• The company's Code of Ethics applies to all officers, directors, and employees.

Next Steps

• Stockholders are encouraged to vote by proxy before the Annual Meeting.
• The company will file a Form 8-K to publish the final voting results after the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Stockholders, Proxy Statement, Board of Directors, Director Election, Executive Compensation, Audit Committee, Deloitte & Touche LLP, Corporate Governance, Minerva Neurosciences